Journal article
Geographic differences in temporal incidence trends of hepatitis C virus infection among people who inject drugs: The InC3 collaboration
MD Morris, S Shiboski, J Bruneau, JA Hahn, M Hellard, M Prins, AL Cox, G Dore, J Grebely, AY Kim, GM Lauer, A Lloyd, T Rice, N Shoukry, L Maher, K Page
Clinical Infectious Diseases | OXFORD UNIV PRESS INC | Published : 2017
DOI: 10.1093/cid/ciw869
Abstract
Background. We determined temporal trends (1985-2011) in hepatitis C virus (HCV) incidence and associated behavioral exposures for people who inject drugs (PWID) from the United States (Boston, Baltimore, and San Francisco), Canada (Montreal), the Netherlands (Amsterdam), and Australia (Sydney and Melbourne). Methods. Using population-based cohort data from HCV-negative PWID, we calculated overall and within-city HCV incidence trends, HCV rates by study enrollment period (1985-2011), and temporal trends in exposure behaviors. Poisson regression models estimated trends in HCV incidence over calendar-time. Survival models identified risk factors for HCV incidence across cities and estimated in..
View full abstractGrants
Awarded by National Institute on Drug Abuse
Funding Acknowledgements
This work was supported by the National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) (R01DA599901). M. D. M. is supported by an NIH/NIDA career development award (K01DA037802) and the NIH National Center for Advancing Translational Sciences (KL2TR000143). Research support for the individual cohorts include The Netherlands National Institute for Public Health and the Environment to the Amsterdam Cohort Study; Baltimore Before and After Study (NIH U19 AI088791); BAHSTION Boston Acute HCV Study: Transmission, Immunity and Outcomes Network (NIH U19 AI066345); Sydney HITS-c - UNSW Hepatitis C Vaccine Initiative and NHMRC Project (grant number 630483); Melbourne Networks/MIX National Health and Medical Research Council, Australia (NHMRC) Project (grant numbers 331312 and 545891) and the Victorian Operational Infrastructure Support Programme (Department of Health, Victoria, Australia); Montreal HepCo-the Canadian Institutes of Health Research (MOP-103138 and MOP-106468); San Francisco (UFO) (NIH/NIDA R01 DA016017).